The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury
Abstract
Background Biochemical markers have not been routinely used in children at risk for myocardial damage. Yet, because of somatic growth and the duration of survival, a low level of myocardial damage may ultimately be of more consequence in children than in adults. Methods and Results We investigated the utility of cardiac troponin T (cTnT) blood levels (CARDIAC T ELISA Troponin T, Boehringer Mannheim Corp) in 51 consecutively sampled patients from 1 day to 34 years of age (median=5.7 years) undergoing cardiovascular (n=19) or noncardiovascular (n=17) surgery or who received doxorubicin for acute lymphoblastic leukemia (ALL) (n=15). Minimum detectable cTnT elevations were 0.03 ng/mL. cTnT was measurable in children of all ages with myocyte damage. In patients who underwent cardiovascular surgery, a correlation was noted between a score of increasing surgical severity and the mean level of postoperative cTnT ( r =.79, P <.0001). Postoperative cTnT levels were elevated in children who completed cardiovascular surgery with an open chest compared with those with a closed chest ( P =.0083). In addition, cTnT levels before cardiovascular surgery predicted postoperative survival ( P =.007). cTnT elevations were observed after initial doxorubicin therapy for ALL. The magnitude of elevation predicted left ventricular dilatation ( r =.80 when variables were treated as continuous, P =.003) and wall thinning ( r =.61, P =.044) 9 months later. Conclusions Elevations of blood cTnT in children relate to the severity of myocardial damage and predict subsequent subclinical and clinical cardiac morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia
Ohman, E. M., Armstrong, P. W., Christenson, R. H., Granger, C. B., Katus, H. A., Hamm, C. W., O’Hanesian, M. A., Wagner, G. S., Kleiman, N. S., Harrell, F. E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610313351801 · Cited by 1,114
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Self-citationNewburger, J. W., Jonas, R. A., Wernovsky, G., Wypij, D., Hickey, P. R., Kuban, K., Farrell, D. M., Holmes, G. L., Helmers, S. L., Constantinou, J., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310073291501 · Cited by 702
Development and In Vitro Characterization of a New Immunoassay of Cardiac Troponin T
Katus, H. A., Looser, S., Hallermayer, K., Remppis, A., Scheffold, T., Borgya, A., Essig, U., & Geuss, U. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.3.386 · Cited by 430
Colan, S. D., Parness, I. A., Spevak, P. J., & Sanders, S. P. (1992) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)80282-7 · Cited by 285
Gerhardt, W., Katus, H., Ravkilde, J., Hamm, C., Jørgensen, P. J., Peheim, E., Ljungdahl, L., & Löfdahl, P. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.8.1405 · Cited by 279
Anderson, P. A. W., Greig, A., Mark, T. M., Malouf, N. N., Oakeley, A. E., Ungerleider, R. M., Allen, P. D., & Kay, B. K. (1995) · Circulation Research · doi:10.1161/01.res.76.4.681 · Cited by 241
Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes
Sarvazyan, N. A. (1996) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1996.271.5.h2079 · Cited by 127
Boutin, C., Wernovsky, G., Sanders, S. P., Jonas, R. A., Castañeda, A. R., & Colan, S. D. (1994) · Circulation · doi:10.1161/01.cir.90.3.1294 · Cited by 71
Elevated donor cardiac troponin I. A marker of acute graft failure in infant heart recipients.
Grant, J. W., Canter, C. E., Spray, T. L., Landt, Y., Saffitz, J. E., Ladenson, J. H., & Jaffe, A. S. (1994) · Circulation · doi:10.1161/01.cir.90.6.2618 · Cited by 51
Myocarditis Associated with Doxorubicin Cardiotoxicity
Gaudin, P. B., Hruban, R. H., Beschorner, W. E., Kasper, E. K., Olson, J. L., Baughman, K. L., & Hutchins, G. M. (1993) · American Journal of Clinical Pathology · doi:10.1093/ajcp/100.2.158 · Cited by 47
Zhang, J., Herman, E., & Ferrans, V. J. (1993) · PubMed · Cited by 44
Cited by
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.023 · Cited by 1,031
“Subclinical cardiac damage may be present as early as the first dose of anthracycline, despite normal LVEF.(39,113) Furthermore, once reduced LVEF develops, irreversible cardiac injury may have potentially occurred.”
BackgroundInfluentialCardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Metadata
- Authors
- Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E.
- Venue
- Circulation
- Published
- 1997-10-21
- Volume
- 96
- Issue
- 8
- Pages
- 2641-2648
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1977566662
- Cited by
- 384
- References
- 12
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.